Search
Arcus Biosciences Inc
RCUSAdd to Watchlist
25.240USD
-0.300-1.17%
Close 09-18 16:00（ET）
3.21BMarket Cap
LossP/E TTM
After-hours 18:30 (ET)25.240USD+0.030+0.12%
After-hours 18:30 (ET)Arcus Biosciences Inc (RCUS) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Arcus Biosciences Inc in the past month.
Buy
3 Strong Buy
7 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
38.750USD+59.33%
RCUS Analyst Recommendation Trends
In the current month, RCUS has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the last month is 38.750.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
7
7
7
6
6
6
6
7
3
3
3
3
3
3
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
13
12
12
12
12
12
RCUS Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, RCUS EPS is projected to reach -0.892 in FY2026Q3, following reported EPS of -0.722 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.03
-0.88
-0.90
-0.89
-0.88
Actual
-0.89
-1.02
-0.72
--
--
Surprise
+12.83%
-16.40%
+19.66%
--
--
FAQs
What is Arcus Biosciences Inc's expected revenue for the next quarter?
Arcus Biosciences Inc's expected revenue is 11.53M.
What is Arcus Biosciences Inc's price target?
Analysts forecast that Arcus Biosciences Inc's price target is USD 38.75, with the highest forecast at USD 47.00 and the lowest forecast at USD 23.00.
How have Arcus Biosciences IncRCUS's recent earnings per share performed?
The market expectation was USD -0.72, while Arcus Biosciences IncRCUS's earnings per share (EPS) for the previous quarter was USD -1.02. EPS for the next quarter is expected at USD -0.89.
What is the analyst rating for Arcus Biosciences Inc?
Based on the ratings of Arcus Biosciences Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.